Literature DB >> 3262089

Recombinant interleukin-1 alpha and recombinant tumor necrosis factor alpha synergize in vivo to induce early endotoxin tolerance and associated hematopoietic changes.

S N Vogel1, E N Kaufman, M D Tate, R Neta.   

Abstract

Endotoxin, the lipopolysaccharide (LPS) derived from gram-negative bacteria, invokes a wide range of responses in susceptible hosts. It is known that virtually all responses to LPS are mediated by the action of macrophage-derived cytokines (such as interleukin-1 [IL-1], tumor necrosis factor [TNF], and others) which are produced principally by macrophages and maximally within several hours of LPS administration. One manifestation of LPS administration which is not well understood is the phenomenon of "early endotoxin tolerance." In response to a single sublethal injection of LPS, experimental animals become refractory to challenge with a homologous or heterologous LPS preparation 3 to 4 days later. Animals rendered tolerant exhibit mitigated toxicity and a reduced capacity to produce circulating cytokines (i.e., colony-stimulating factor or interferon) in response to the challenge LPS injection. Previous studies have also shown that this state of transient, acquired hyporesponsiveness to LPS is accompanied by a marked increase in the size of cells in the bone marrow which are enriched in numbers of macrophage progenitors. In this study, we examined the capacity of recombinant IL-1 or recombinant TNF or both to induce early endotoxin tolerance and its associated hematopoietic changes. Neither cytokine alone was able to mimic LPS for induction of tolerance. Combined administration of recombinant IL-1 and recombinant TNF doses which were not toxic when administered individually led to synergistic toxicity (as assessed by death or weight loss). However, within a nontoxic range, the two cytokines synergized to induce a significant reduction in the capacity to produce colony-stimulating factor in response to LPS, as well as the characteristic increase in bone marrow cell size and macrophage progenitors shown previously to be associated with LPS-induced tolerance.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262089      PMCID: PMC259625          DOI: 10.1128/iai.56.10.2650-2657.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Interleukin 1: a common endogenous mediator of inflammation and the local Shwartzman reaction.

Authors:  G Beck; G S Habicht; J L Benach; F Miller
Journal:  J Immunol       Date:  1986-04-15       Impact factor: 5.422

2.  Interferon appearance stimulated by endotoxin, bacteria, or viruses in mice pre-treated with Escherichia coli endotoxin or infected with Mycobacterium tuberculosis.

Authors:  J S Youngner; W R Stinebring
Journal:  Nature       Date:  1965-10-30       Impact factor: 49.962

3.  The role of the liver in the production of fever and in pyrogenic tolerance.

Authors:  C A Dinarello; P T Bodel; E Atkins
Journal:  Trans Assoc Am Physicians       Date:  1968

4.  Early endotoxin tolerance is associated with alterations in bone marrow-derived macrophage precursor pools.

Authors:  G S Madonna; S N Vogel
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

5.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

6.  Early-phase endotoxin tolerance: induction by a detoxified lipid A derivative, monophosphoryl lipid A.

Authors:  G S Madonna; J E Peterson; E E Ribi; S N Vogel
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

7.  Silica enhancement of murine endotoxin sensitivity.

Authors:  S N Vogel; K E English; A D O'Brien
Journal:  Infect Immun       Date:  1982-11       Impact factor: 3.441

8.  Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells.

Authors:  B A Beutler; A Cerami
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

9.  Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance.

Authors:  B Beutler; N Krochin; I W Milsark; C Luedke; A Cerami
Journal:  Science       Date:  1986-05-23       Impact factor: 47.728

10.  Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.

Authors:  C A Dinarello; J G Cannon; S M Wolff; H A Bernheim; B Beutler; A Cerami; I S Figari; M A Palladino; J V O'Connor
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

View more
  24 in total

Review 1.  Bloodstream infections: epidemiology, pathophysiology and therapeutic perspectives.

Authors:  R Salomão; O Rigato; A C Pignatari; M A Freudenberg; C Galanos
Journal:  Infection       Date:  1999 Jan-Feb       Impact factor: 3.553

2.  SDZ MRL 953, a novel immunostimulatory monosaccharidic lipid A analog with an improved therapeutic window in experimental sepsis.

Authors:  C Lam; E Schütze; J Hildebrandt; H Aschauer; E Liehl; I Macher; P Stütz
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance.

Authors:  B E Henricson; W R Benjamin; S N Vogel
Journal:  Infect Immun       Date:  1990-08       Impact factor: 3.441

4.  An interleukin-1 receptor antagonist blocks lipopolysaccharide-induced colony-stimulating factor production and early endotoxin tolerance.

Authors:  B E Henricson; R Neta; S N Vogel
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

5.  Roles of interleukin-1 and tumor necrosis factor in lipopolysaccharide-induced hypoglycemia.

Authors:  S N Vogel; B E Henricson; R Neta
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

6.  Altered in vivo activity of liposome-incorporated lipopolysaccharide and lipid A.

Authors:  J Dijkstra; J W Mellors; J L Ryan
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

7.  Tolerance to endotoxin-induced expression of the interleukin-1 beta gene in blood neutrophils of humans with the sepsis syndrome.

Authors:  C E McCall; L M Grosso-Wilmoth; K LaRue; R N Guzman; S L Cousart
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

8.  Differential regulation of cytokine production in lipopolysaccharide tolerance in mice.

Authors:  A Erroi; G Fantuzzi; M Mengozzi; M Sironi; S F Orencole; B D Clark; C A Dinarello; A Isetta; P Gnocchi; M Giovarelli
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

9.  Antibody-mediated enhancement of Legionella pneumophila-induced interleukin 1 activity.

Authors:  R H Widen; C A Newton; T W Klein; H Friedman
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

10.  Induction of circulating tumor necrosis factor cannot be demonstrated during septicemic salmonellosis in calves.

Authors:  J E Peel; M J Voirol; C Kolly; D Gobet; S Martinod
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.